16:07 , Aug 10, 2018 |  BioCentury  |  Finance

Missing the obvious

Despite the vast amount of venture money being poured into innovation in healthcare, women’s health still remains an underserved market with significant untapped potential. The importance of this for public health is often overlooked in favor...
17:45 , Jul 20, 2018 |  BC Week In Review  |  Clinical News

Levo's LV-101 improves hyperphagia and behavioral symptoms in Phase II for Prader-Willi

Levo Therapeutics Inc. (Chicago, Ill.) reported data from a Phase II trial in 37 patients with genetically confirmed Prader-Willi syndrome (PWS) showing that intranasal LV-101 given thrice daily before meals reduced mean Hyperphagia in PWS...
19:03 , Jun 22, 2018 |  BC Week In Review  |  Financial News

ObsEva raises $73M follow-on

Reproductive health company ObsEva S.A. (NASDAQ:OBSV) raised $73.1 million through the sale of 4.8 million shares at $15.39 in a follow-on underwritten by J.P. Morgan, Credit Suisse Securities (USA), Jefferies, Wedbush Securities and H.C. Wainwright....
20:13 , Jun 20, 2018 |  BC Extra  |  Financial News

ObsEva raises $73M on heels of linzagolix data

ObsEva S.A. (NASDAQ:OBSV) raised $73.1 million through the sale of 4.8 million shares at $15.39 in a follow-on underwritten by J.P. Morgan, Credit Suisse Securities (USA), Jefferies, Wedbush Securities and H.C. Wainwright. The price is...
18:01 , Mar 23, 2018 |  BC Week In Review  |  Clinical News

ObsEva's nolasiban meets in Phase III to improve pregnancy rates

ObsEva has exclusive, worldwide rights to nolasiban from Merck KGaA (Xetra:MRK) under a 2013 deal. ObsEva S.A. (NASDAQ:OBSV), Geneva, Switzerland  Merck KGaA (Xetra:MRK), Darmstadt, Germany  Product: Nolasiban (formerly OBE001)  Business: Genitourinary  Molecular target: Oxytocin receptor (OXTR)  Description: OXTR antagonist  Indication: Improve pregnancy...
00:34 , Oct 20, 2017 |  BC Week In Review  |  Financial News

OptiNose raises $138M in IPO

OptiNose Inc. (NASDAQ:OPTN) raised $138 million through the sale of 8.6 million shares at $16 in an IPO underwritten by Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets. The price was at the...
20:31 , Oct 13, 2017 |  BC Extra  |  Financial News

OptiNose rises after pricing $120M IPO

OptiNose Inc. (NASDAQ:OPTN) gained $3 (19%) to $19 in its first day of trading Friday after it raised $120 million through the sale of 7.5 million shares at $16 in an IPO underwritten by Jefferies,...
03:45 , Apr 7, 2017 |  BC Innovations  |  Strategy

Pushing for progress in Prader-Willi

In the wake of the 2015 clinical failure of Zafgen Inc.’s subcutaneous beloranib for obesity in Prader-Willi syndrome patients, the Foundation for Prader-Willi Research (FPWR) last year launched a five-year, $26 million strategic research plan...
00:59 , Mar 30, 2017 |  BC Week In Review  |  Clinical News

Nolasiban: Ph III IMPLANT2 started

ObsEva began the double-blind, placebo-controlled, European Phase III IMPLANT2 trial to evaluate single doses of 900 mg oral nolasiban before fresh embryo transfer on day 3 or day 5 following egg retrieval in about 760...
18:00 , Feb 15, 2017 |  BC Innovations  |  Distillery Therapeutics

Other

INDICATION: Genetic disorders Studies in rats suggest oxytocin could help treat the autism-like symptoms of Phelan-McDermid syndrome (PMDS), which is caused by SHANK3 mutations. In a SHANK3-knockout rat model of Phelan-McDermid syndrome, intraventricular injection of oxytocin...